The short version
- Why people research itFocus, memory, neuroprotection, mood and stress resilience.
- What the evidence isThe human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
- What to watchNew indigestion or reflux.
How GB-115 works
The molecule, written out. GB-115 is the amide of N-phenylhexanoyl-glycyl-L-tryptophan Sorokina 2010 Boyko 2007.
What it is a copy of. Cholecystokinin-4 is Trp-Met-Asp-Phe-NH2, the C-terminal tetrapeptide of cholecystokinin and the most reliable experimental panicogen in human research: infuse it and healthy volunteers get panic. GB-115 is described in its own literature as a retro-analog of CCK-4 Kolik 2012 Kolik 2013 — the recognition element rebuilt with the residue order reversed, which is why a Gly-Trp dipeptide can present the same beta-turn as a tetrapeptide does.
- Oral
- Nasal
On the goal map: HPA axis & cortisol regulation (Mood & stress resilience)
Research on GB-1154 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Russian preclinical and early clinical work, little of it in English or peer-reviewed internationally.
Human clinical evidence
The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
Correlative data
Very limited use outside Russian research settings. There is almost no community record, which means the clinical tier above is effectively the entire human evidence base for it.
How the mechanism reads
A dipeptide cholecystokinin (CCK) antagonist developed at the Russian Institute of Pharmacology. CCK-B receptor activation provokes panic in humans experimentally, so blocking it is a coherent anxiolytic target.
MechanisticThat mechanism is unusual and interesting — it addresses anxiety without touching GABA, so it predicts no sedation and no dependence liability. It also predicts a narrower effect, since it targets one specific panic pathway.
Mechanistic
Sources
- Boyko SS, Kolyvanov GB, Zherdev VP, Gudasheva TA, Kiryanova EP, Seredenin SB. Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115. Bulletin of Experimental Biology and Medicine 2007 · PMID 18457023
- Sorokina AV, Alekseeva SV, Nemova EP, Kovalenko LP, Smol'nikova NM, Shipaeva EV, et al. Preclinical safety investigation of GB-115 dipeptide. Eksperimentalnaia i Klinicheskaia Farmakologiia 2010 · PMID 20726348
- Kolik LG, Gudasheva TA, Seredenin SB. Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115. Bulletin of Experimental Biology and Medicine 2012 · PMID 23113301
- Kolik LG, Konstantinopolsky MA, Ryibina IV, Povarnina PY, Gudasheva TA, Seredenin SB. Anxiolytic activity of dipeptide GB-115 after oral administration. Bulletin of Experimental Biology and Medicine 2013 · PMID 24130989
- Ivannikova EV, et al. Pharmacokinetics of three peroral dosage forms of new dipeptide anxiolytic drug GB-115. Eksperimentalnaia i Klinicheskaia Farmakologiia 2014 · PMID 25322652
- Gudasheva TA. Novel Technologies for Dipeptide Drugs Design and their Implantation. Current Pharmaceutical Design 2018 · PMID 30295186
- Neznamov GG, et al. Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors. Zhurnal Nevrologii i Psikhiatrii im S S Korsakova 2019 · PMID 31626171
GB-115 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Persistent indigestion or ulcer disease, since CCK-B is also the gastrin receptor in the stomach.
- Taking benzodiazepines or other anxiety drugs without knowing how they stack.
- Pregnancy or breastfeeding, where the dipeptide's transfer is unmeasured.
- Under 18, while CCK-B pathways are still developing in brain and gut.
What’s expected
- Reduced anxious reactivity without sedation, since it does not touch GABA.
- Lower stomach acid output from gastrin receptor blockade.
- Preclinical safety work was clean.
Watch for
- New indigestion or reflux.
- A return of panic symptoms.
- Unusual fatigue or tingling over time.
Labs that tell you it’s working
- Vitamin B12: lower stomach acid reduces its absorption.
- Ferritin: acid is needed to absorb iron.
- Magnesium: low gastric acid can lower magnesium uptake.
Dipeptide CCK-B receptor antagonist: blocks the panic-linked CCK-4 receptor, and the same receptor drives gastrin-stimulated acid output. PMID 20726348 PMID 23113301
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
GB-115 FAQ4 common questions
- Is GB-115 approved for human use?
- No. GB-115 is a research compound.
- What is GB-115 researched for?
- Focus, memory, neuroprotection, mood and stress resilience.
- Which labs show whether it's doing anything?
- Vitamin B12; Ferritin; Magnesium: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for GB-115: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



